Kynam Capital Management, LP
PRINCETON, NJ · CIK 1907884 · 13F filing filed 2022-05-13
SEC-registered investment adviser since 2022 · limited partnership
- Assets managed$2.4bn
- Staff3 · 2 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds1 (1 hedge) · $2.4bn gross assets
- Form ADV · 2026-04-10SEC adviser record
- Legal entityKYNAM CAPITAL MANAGEMENT, LP (US)
- Kindhedge funds, futures
- Others nearbyPrinceton, NJ
As an employer
- Private fundshedge 1
$307.6m
reported value
+64.5% vs Q4 2021
31positions
76.3%in top 10
3 new
13 added
15 reduced
2 sold out
vs Q4 2021
Options: 0 call positions (— notional), 2 put positions ($661.0k notional) – listed below, not included above.
Holdings, Q1 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| GLOBAL BLOOD THERAPEUTICS IN GBT | $46.4m15.08% | Added +346.4k |
| NATERA INC NTRA | $39.3m12.78% | New |
| SYNDAX PHARMACEUTICALS INC SNDX | $33.6m10.92% | Added +976.6k |
| CELLDEX THERAPEUTICS INC NEW CLDX | $25.6m8.34% | Added +526.3k |
| TRAVERE THERAPEUTICS INC TVTX | $22.4m7.30% | Added +688.8k |
| GOSSAMER BIO INC GOSS | $15.9m5.17% | Added +815.8k |
| XENON PHARMACEUTICALS INC XENE | $14.8m4.80% | Reduced -186.8k |
| VAXCYTE INC PCVX | $14.0m4.55% | Added +368.2k |
| VERA THERAPEUTICS INC VERA | $11.8m3.84% | Added +248.9k |
| VIRIDIAN THERAPEUTICS INC VRDN | $10.9m3.55% | Added +301.9k |
| LIQUIDIA CORPORATION LQDA | $8.3m2.71% | Reduced -207.2k |
| BIOGEN INC BIIB | $8.1m2.62% | Reduced -1.8k |
| AMARIN CORP PLC SPONS ADR NEW | $7.5m2.45% | Added +83.2k |
| BURNING ROCK BIOTECH LTD SPONSORED ADS | $7.2m2.33% | Added +390.6k |
| SIERRA ONCOLOGY INC COM NEW | $6.2m2.01% | New |
| CENTESSA PHARMACEUTICALS PLC SPONSORED ADS | $6.0m1.95% | Added +430.1k |
| AMICUS THERAPEUTICS INC FOLD | $5.4m1.77% | Reduced -183 |
| WAVE LIFE SCIENCES LTD 96663EUR | $3.8m1.24% | Added +417.1k |
| FATE THERAPEUTICS INC FATE | $3.5m1.15% | Reduced -4.2k |
| MERUS N V MRUS | $3.1m1.00% | Reduced -5.4k |
| SERES THERAPEUTICS INC COM | $2.1m0.67% | Reduced -13.5k |
| PUMA BIOTECHNOLOGY INC PBYI | $1.9m0.61% | Reduced -30.2k |
| AKOUOS INC COM | $1.8m0.60% | Added +288.9k |
| RADIUS HEALTH INC RDUS | $1.6m0.53% | Reduced -8.6k |
| AFFIMED N V COM | $1.5m0.49% | Reduced -16.1k |
| CABALETTA BIO INC CABA | $1.3m0.41% | Reduced -28.5k |
| KRYSTAL BIOTECH INC KRYS | $1.2m0.40% | Reduced -16.4k |
| OLEMA PHARMACEUTICALS INC OLMA | $1.2m0.39% | Reduced -13.0k |
| CONNECT BIOPHARMA HLDGS LTD ADS | $688.0k0.22% | New |
| NEOLEUKIN THERAPEUTICS INC COM | $264.0k0.09% | Reduced -6.5k |
| CATALYST BIOSCIENCES INC COM NEW | $70.0k0.02% | Reduced -4.9k |
Sold out since Q4 2021
| Security | Value then |
|---|---|
| ZOGENIX INC ZGNX | $3.3m205.8k shares |
| COGENT BIOSCIENCES INC COGT | $1.3m150.0k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| TG THERAPEUTICS INC TGTX · Put | $401.0k258.6k shares | New |
| NEKTAR THERAPEUTICS Put | $260.0k200.0k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| BURNING ROCK BIOTECH LTD 13G · filed 2026-05-15 | 14.0% |
| SYNDAX PHARMACEUTICALS INC SNDX · 13G · filed 2025-02-14 | 10.0%≈ $186.2m |
| CYTOMX THERAPEUTICS INC CTMX · 13G · filed 2026-08-14 | 10.0% |
| CELLDEX THERAPEUTICS INC NEW CLDX · 13G · filed 2026-08-14 | 6.8% |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 5.7% |
| SUTRO BIOPHARMA INC 13G · filed 2026-05-15 | 5.3% |
| CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2026-03-04 | 5.3%≈ $56.7m |